<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01217632</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-3019-801</org_study_id>
    <nct_id>NCT01217632</nct_id>
  </id_info>
  <brief_title>A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection</brief_title>
  <official_title>A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this trial is to evaluate the efficacy of FG-3019 for reversing liver
      fibrosis in subjects with chronic hepatitis B infection who are beginning antiviral therapy
      with entecavir. This Phase 2 randomized, double-blind, placebo controlled study will enroll
      subjects with chronic active hepatitis B infection and liver fibrosis (Ishak score ≥2) who
      are eligible for antiviral therapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to an unexpected prominent effect of entecavir alone in this patient
    population.
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the efficacy of FG-3019 administered every 3 weeks for 45 weeks on liver fibrosis in subjects with chronic active hepatitis B infection on entecavir therapy</measure>
    <time_frame>every 3 weeks for 45 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety, tolerability pharmacokinetic profiles of FG-3019 in the target population</measure>
    <time_frame>every 3 weeks for 45 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Liver Fibrosis Due to Chronic Hepatitis B Infection</condition>
  <arm_group>
    <arm_group_label>FG-3019 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered at 15-45 mg/kg every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FG-3019</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-3019</intervention_name>
    <description>FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.</description>
    <arm_group_label>FG-3019</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered every 3 weeks by intravenous (IV) infusion in a total volume of at least 250 mL in normal saline.</description>
    <arm_group_label>FG-3019 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <arm_group_label>FG-3019 Placebo</arm_group_label>
    <arm_group_label>FG-3019</arm_group_label>
    <other_name>Entecavir Dispersible (generic)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Signed informed consent

          -  Age of 18 to 75 years, inclusive

          -  HBsAg positive for ≥24 weeks prior to screening

          -  Liver fibrosis, confirmed by biopsy and histology

          -  Willing to use contraception

        Exclusion Criteria:

          -  Female subjects who are pregnant or nursing

          -  Prior antiviral therapy, with the exception of interferon therapy &gt;6 months prior to
             Day 1

          -  Severe heart failure

          -  Present hepatocellular carcinoma and history of other cancers

          -  Severe anemia

          -  Advanced kidney disease

          -  Immunosuppressive therapy within 24 weeks prior to screening

          -  Alcohol or drug abuse within the 12 months prior to screening

          -  Trauma or surgical procedures requiring hospitalization within 8 weeks prior to Day 1

          -  Planned elective surgery during the study including 9 weeks following the final dose
             of study drug

          -  History of allergy against nucleoside analogs or human, humanized, chimeric, or murine
             monoclonal antibodies

          -  Inability to cooperate with study personnel or a history of noncompliance to the
             medical regimen (i.e., subjects who would be expected to comply poorly with the
             treatment)

          -  Clinically significant medical or psychiatric condition considered a high risk for
             participation in an investigational study

          -  Morbid obesity (body mass index [BMI] &gt;40)

          -  Inadequate IV access
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Valone, MD</last_name>
    <role>Study Chair</role>
    <affiliation>FibroGen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mairead Carney</last_name>
    <role>Study Director</role>
    <affiliation>FibroGen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Pokfulam</city>
        <state>Hong Kong Island</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruttonjee Hospital</name>
      <address>
        <city>Wanchai</city>
        <state>Hong Kong Island</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <state>Kowloon</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alice Ho Miu Ling Nethersole Hospital</name>
      <address>
        <city>Tai Po</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Siriaj</city>
        <state>Bangkok Noi</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Amphur Muang</city>
        <state>Chiang Mai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Amphur Hatyai</city>
        <state>Songkla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2010</study_first_submitted>
  <study_first_submitted_qc>October 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2010</study_first_posted>
  <last_update_submitted>August 12, 2016</last_update_submitted>
  <last_update_submitted_qc>August 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Connective tissue growth factor (CTGF)</keyword>
  <keyword>human IgG1 monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

